title: CYP2C19 polymorphism in Korean patients on warfarin therapy.
abstract: This study was designed to assess the effect of CYP2C19 polymorphism on warfarin dosage requirements and bleeding complications in the Korean population. Patients were placed into one of four groups according to the dose of warfarin they received and the presence of bleeding complications: regular dose control, regular dose bleeding, low dose control, and low dose bleeding. Genotyping for CYP2C19*2 and CYP2C19*3 was performed by the restriction fragment length polymorphism method for each patient and each study group. The measured internal normalized ratio (INR) in each dose group was similar even though the administered dosage was significantly different. A total of 66 patients were evaluated for CYP2C19 polymorphism. Among them 25 patients (37.9%) were homozygous wild type. Four patients (6.1%) had heterozygous mutations at both loci. Others had mutations on either the CYP2C19*2 or *3 locus. Higher genetic variation was observed in CYP2C19*2 than in CYP2C19*3 among Korean patients on warfarin therapy. Our data suggested that there is a higher incidence of bleeding complications in patients who have a higher allele frequency of CYP2C19. It was also revealed that the distribution of CYP2C19 polymorphism among Asian populations is more similar than of the distribution among Caucasian populations.
authors.affiliation: Graduate School of Clinical Pharmacy, Sookmyung Women's University, Seoul 140-742, Korea.
authors.forename: Sukhyang
authors.initials: S
authors.lastname: Lee
authors.forename: Hyun Jin
authors.initials: HJ
authors.lastname: Hwang
authors.forename: Jae-Moon
authors.initials: JM
authors.lastname: Kim
authors.forename: Chin-Sang
authors.initials: CS
authors.lastname: Chung
authors.forename: Jeong Hee
authors.initials: JH
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D044466:Asian People; D065731:Cytochrome P-450 CYP2C19; D005260:Female; D005838:Genotype; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009154:Mutation; D011110:Polymorphism, Genetic; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D014859:Warfarin; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19